SAN DIEGO, Feb. 20, 2019 /PRNewswire/ -- Arena
Pharmaceuticals, Inc. (Nasdaq: ARNA) will announce its fourth
quarter and full-year 2018 financial results on Tuesday, February 26, 2019, after the close of
the U.S. financial markets. The Company will host a conference call
and live webcast to discuss the results with the investment
community the same day at 4:30 p.m.
EST.
Conference Call & Webcast Information
When:
February 26, 2019, 4:30 p.m. EST
Dial-in: (877) 643-7155 (United
States) or (914) 495-8552 (International)
Conference ID: 1855406
Please join the conference call at least 10 minutes early to
register. You can access the live webcast under the investor
relations section of Arena's website at: www.arenapharm.com. A
replay of the conference call will be archived under the investor
relations section of Arena's website for 30 days after the
call.
About Arena Pharmaceuticals
Arena Pharmaceuticals is
driven to deliver novel, transformational medicines with optimized
pharmacology and pharmacokinetics to patients globally. Arena's
proprietary pipeline includes multiple potentially first- or
best-in-class assets with broad clinical utility.
Etrasimod (APD334), with potential utility in a broad range of
immune and inflammatory conditions, is being evaluated in
later-stage clinical programs in ulcerative colitis (UC) and
Crohn's disease, as well as in programs for other indications such
as atopic dermatitis. Arena is also evaluating olorinab (APD371) in
a Phase 2 program for gastrointestinal pain. Arena continues to
assess other earlier research and development stage drug
candidates, including APD418 for decompensated heart failure.
Arena's licensee, United Therapeutics, is evaluating ralinepag in a
Phase 3 program for pulmonary arterial hypertension (PAH).
Arena has additional license agreements and partnerships,
including with Everest Medicines Limited (etrasimod in Greater China and select Asian countries),
Boehringer Ingelheim International GmbH (undisclosed target –
preclinical), Outpost Medicine, LLC (undisclosed target –
preclinical), and Eisai Co., Ltd. and Eisai Inc.
(BELVIQ® – marketed product).
Forward-Looking Statements
Certain statements in this
press release are forward-looking statements that involve a number
of risks and uncertainties. Such forward-looking statements include
statements about Arena's upcoming conference call and live webcast
with the investment community, Arena's drive, and the potential of
Arena's assets, programs, collaborations, and licenses. For such
statements, Arena claims the protection of the Private Securities
Litigation Reform Act of 1995. Actual events or results may differ
materially from Arena's expectations. Factors that could cause
actual results to differ materially from the forward-looking
statements include those disclosed in Arena's filings with the
Securities and Exchange Commission. These forward-looking
statements represent Arena's judgment as of the time of this
release. Arena disclaims any intent or obligation to update these
forward-looking statements, other than as may be required under
applicable law.
Corporate
Contact:
Kevin R. Lind
Arena Pharmaceuticals, Inc.
Executive Vice President and
Chief Financial
Officer
klind@arenapharm.com
858.210.3636
Media Contact:
Matt Middleman, MD
LifeSci Public Relations
matt.middleman@lifescipublicrelations.com
646.627.8384
View original content to download
multimedia:http://www.prnewswire.com/news-releases/arena-pharmaceuticals-to-announce-fourth-quarter-and-full-year-2018-financial-results-and-provide-corporate-update-on-february-26-300799104.html
SOURCE Arena Pharmaceuticals, Inc.